Comparison of colistin / rifampin combination with colistin / meropenem combination in the treatment of ventilator-dependent upper respiratory tract (VAP) induced by Acinetobacter: a randomized controlled clinical trial

Evaluation of the effectiveness of colistin / rifampin compared to colistin / meropenem in the treatment of ventilator-associated pneumonia (VAP) due to carbapenem-resistant Acinetobacter baumannii: a randomized, controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150721023282N22

Enrollment

Registered

2022-07-24

Start date

2022-08-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-induced pneumonia. Ventilator associated pneumonia

Interventions

Intervention 1: Intervention group: colistin (Product of Exir pharmaceutical company , 4.5 MU IV q12h) + rifampin (Product of Hakim Pharmaceutical Company , 300 mg PO q12h), for 10 days. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Under mechanical ventilation (intubation) for more than 48 hours VAP diagnosis Growth of carbapenem (meropenem)-resistant Acinetobacter baumannii in the lung secretions culture

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Sensitivity to meropenem, colistin, or levofloxacin Acute Respiratory Distress Syndrome Active pulmonary tuberculosis

Design outcomes

Primary

Measure	Time frame
Clinical Response (defined as cure or improvement or treatment failure). Timepoint: End of intervention. Method of measurement: Clinical judgment by the observation of the patient.	—

Secondary

Measure	Time frame
Clinical Pulmonary Infection Score (CPIS). Timepoint: Before and after the intervention. Method of measurement: Questionnaire - Clinical Pulmonary Infection Scoring System.;Mortality rate during the intervention. Timepoint: The end of intervention. Method of measurement: Counting.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasool Soltani

Esfahan University of Medical Sciences

soltani@pharm.mui.ac.ir+98 31 3792 7067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026